BioCardia (BCDA) EBITDA (2010 - 2026)

BioCardia (BCDA) has reported EBITDA for 15 consecutive years, with -$1.6 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, EBITDA rose 20.87% year-over-year to -$1.6 million in Q2 2026; TTM through Jun 2026 was -$7.4 million, a 16.11% increase from a year earlier, with the FY2024 full-year figure at -$8.0 million, up 31.29% from the prior year.
• EBITDA was -$1.6 million for Q2 2026 at BioCardia, up from -$2.3 million in the prior quarter.
• Over five years, EBITDA peaked at -$1.5 million in Q3 2025 and troughed at -$3.5 million in Q1 2023.
• A 5-year average of -$2.5 million and a median of -$2.3 million in 2024 frame the typical range for EBITDA.
• Across the five-year window, EBITDA slumped 38.3% in 2023 and jumped 52.23% in 2024, its largest moves.
• Over 5 years, EBITDA stood at -$3.0 million in 2022, then soared by 30.95% to -$2.1 million in 2023, then decreased by 11.37% to -$2.3 million in 2024, then surged by 35.89% to -$1.5 million in 2025, then decreased by 9.07% to -$1.6 million in 2026.
• The last three EBITDA figures came in at -$1.6 million (Q2 2026), -$2.3 million (Q1 2026), and -$1.5 million (Q3 2025), per Business Quant data.